Zheng Quan Zhi Xing·2025-08-29 16:41Core Viewpoint - The company has decided to permanently supplement its working capital with surplus funds from completed fundraising projects, following a thorough review and approval process [1][8][9] Fundraising Overview - The company raised a net amount of 829.37 million yuan after deducting issuance costs of 91.96 million yuan [1] - The funds were verified by an accounting firm and stored in a dedicated account with a tripartite supervision agreement [1] Investment Project Status - As of June 30, 2025, the company has invested a total of 733.62 million yuan in various projects, with a remaining balance of 299.67 million yuan [2] - The "Annual Production of 400 Million Medical Devices (In Vitro Diagnostics) Expansion and Upgrade Project" has been completed and is now operational [3][4] Surplus Funds and Their Use - The company has approved the use of 160.57 million yuan in surplus funds to support daily operations, following the completion of certain projects [3][6] - The surplus funds were generated due to cost-saving measures during project implementation, including optimized production processes and reduced personnel costs [4][6] Financial Performance of Completed Projects - The completed project generated revenues of 47.11 million yuan in 2023, 112.07 million yuan in 2024, and 13.92 million yuan in the first half of 2025, which did not meet the expected performance [6] Decision-Making Process - The decision to use surplus funds for working capital was made after careful consideration of market conditions and project completion [7][8] - The board of directors approved the proposal without requiring a shareholder meeting [7] Conclusion from the Sponsor Institution - The sponsor institution has confirmed that the decision to use surplus funds aligns with regulatory requirements and is beneficial for the company's long-term development [8][9]